Keyphrases
Human Influenza
100%
World Health Organization
100%
Neuraminidase Inhibitors
100%
Neuraminidase
100%
Virus
85%
Influenza
42%
H275Y
42%
United States
28%
A(H1N1)pdm09
28%
Oseltamivir
28%
Collaborating Centre
28%
Europe
14%
China
14%
B-type
14%
Public Health Perspective
14%
Type-specific
14%
Phylogenetic Analysis
14%
Zanamivir
14%
Sequence Data
14%
H3N2
14%
Amino Acid Substitution
14%
Sequence Database
14%
Past Exposure
14%
Japan
14%
Global Surveillance
14%
Multiple Resistance
14%
Resistance Emergence
14%
Antiviral Susceptibility
14%
IC50
14%
Western Pacific
14%
50% Inhibitory Concentration
14%
Surveillance Epidemiology
14%
Influenza Antivirals
14%
Laninamivir
14%
Peramivir
14%
Victoria Lineage
14%
Large Community
14%
E119V
14%
Influenza A(H1N1)pdm09 Virus
14%
Yamagata Lineage
14%
Amino Acid Position
14%
Hokkaido
14%
Community Clusters
14%
Hokkaido Japan
14%
One World
14%
Medicine and Dentistry
Influenza Virus
100%
Sialidase
100%
Sialidase Inhibitor
100%
Virus
100%
Influenza A Virus (H1N1)
42%
Oseltamivir
28%
IC50
28%
Public Health
14%
Cohort Effect
14%
Zanamivir
14%
Amino Acid
14%
Influenza A Virus (H3N2)
14%
Antiviral Susceptibility
14%
Amino Acid Substitution
14%
Peramivir
14%
Laninamivir
14%
Antiviral Drug
14%
Immunology and Microbiology
Influenza Virus
100%
Virus
100%
Neuraminidase Inhibitor
100%
Influenza
57%
Influenza A Virus (H1N1)
42%
Lineages
28%
IC50
28%
Influenza A Virus (H3N2)
14%
Amino Acid Substitution
14%
Sequence Database
14%
Relenza
14%
Antiviral Susceptibility
14%
Cladistics
14%
Amino Acid
14%
Pharmacology, Toxicology and Pharmaceutical Science
Influenza Virus
100%
Sialidase
100%
Sialidase Inhibitor
100%
Influenza A Virus (H1N1)
42%
Amino Acid
28%
Oseltamivir
28%
IC50
28%
Relenza
14%
Antivirus Agent
14%
Influenza A Virus (H3N2)
14%
Laninamivir
14%
Peramivir
14%
Antiviral Drug
14%